Sir,

The results of the postal survey by Kumar and Jivan on screening for Vigabatrin-related visual field defects has yielded some interesting data reflecting the application of guidelines in the real world. Busy clinicians are naturally averse to extra service load and there are always communication issues between hospital specialists. However, it is worth pointing out that Vigabatrin has now largely been replaced by newer agents without this side effect for the control of refractory epilepsy, so the number of epileptic patients with visual impairment from this phenomenom is limited. Although the field loss is not treatable, recognition and appropriate visual impairment registration is still beneficial to the patient.